Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer

Journal of B.U.ON.

Volumn 11, Issue 4, 2006, Pages 499-504

  Chavdarova, Lidia ^a   Piperkova, E ^a   Tsonevska, A ^a   Timcheva, K ^a   Dimitrova, M ^a  

^a National Oncology Center Bulgaria   (Bulgaria)

Author keywords

Biphosphonates; Bone metastases; Bone scintigraphy; Breast cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; MEDRONATE TECHNETIUM TC 99M; ZOLEDRONIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM TC 99M HYDROXYMETHYLENE DIPHOSPHONATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; BONE TUMOR; BREAST TUMOR; FEMALE; METASTASIS; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE; WHOLE BODY IMAGING;

EID: 33947526775     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Demirkan B, Baskan Z, Alacacioglu A et al. False negative bone scintigraphy in a patient with primary breast cancer: a possible transient phenomenon of bisphosphonate (alendronate) treatment. Tumori 2005; 91: 77-80.
2. Fleisch H (ed): Bisphosphonates in bone disease: From the laboratory to the patients. Academic Press: San Diego, London, 2000.
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
4. Rizzoli R. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer. Ann Oncol 2004; 15: 700-701.
5. Pecherstorfer M, Schilling T, Janisch S et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993; 34: 1039-1044.
6. Musat E, Stefanescu C, Rusu V. Whole-body bone scintigraphy in the diagnosis and follow-up of the evolution of breast cancer. Rev Med Chir Soc Med Nat, Iasi 1999; 103: 163-169.
7. Hamaoka T, Madewell J, Podoloff D, Hortobagyi GN, Ueno N. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22: 2942-2953.
8. Einat ES. Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. J Nucl Med 2005; 46: 1356-1367.
9. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-2044.
10. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846-854.
11. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
12. Body JJ, Diel JJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405.
13. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
14. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 20: CD003474.
15. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: 897-907.
16. Body JJ, Diel IJ, Tripathy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 2006; 15: 299-302.
17. Oura S, Sakurai T, Yoshimura G et al. Pain relief with alendronate therapy in a breast cancer patient with bone metastasis. Gan To Kagaku Ryoho 2000; 27: 633-637.
18. Yokoyama H, Nakatsuka K, Shoji T, Kawasaki I, Inaba M, Nishizawa Y. Intravenous pamidronate delivery to a case with multiple bone metastases of breast cancer. Nippon Ronen Igakkai Zasshi 2001; 38: 812-815.
19. Suzuma T, Sakurai T, Yoshimura G et al. Pamidronate induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy refractory inoperable metastatic breast carcinoma. Anticancer Drugs 2001; 12: 731-734.
20. Sueyoshi K, Ogura Y, Komori T et al. A case of effective bisphosphonate therapy for bone metastasis from breast cancer with multiorganic metastases. Gan To Kagaku Ryoho 2002; 29: 1795-1799.
21. Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y. Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer- a case report. Gan To Kagaku Ryoho 1999; 26: 1469-1473.
22. Tjalma WA, Buytaert PM, Berneman ZN. Reduction of visible bone metastases by clodronate therapy in breast cancer. Eur J Gynaecol Oncol 2001; 22: 215-216.
23. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006.8:R13 doi:10.1186/bcr1384.
24. Schirrmeister H, Guhlman A, Kotzerke J et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17: 2381-2383.